TR200102577T2 - Kanser Tedavisi için Casb616 Polipeptid ve Polinücleotidlerin kullanımı - Google Patents
Kanser Tedavisi için Casb616 Polipeptid ve Polinücleotidlerin kullanımıInfo
- Publication number
- TR200102577T2 TR200102577T2 TR2001/02577T TR200102577T TR200102577T2 TR 200102577 T2 TR200102577 T2 TR 200102577T2 TR 2001/02577 T TR2001/02577 T TR 2001/02577T TR 200102577 T TR200102577 T TR 200102577T TR 200102577 T2 TR200102577 T2 TR 200102577T2
- Authority
- TR
- Turkey
- Prior art keywords
- polynucleotides
- casb616
- polypeptide
- cancer treatment
- cancers
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Catalysts (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Abstract
Özellikle kolon kanserleri, otoimmün hastaliklar ve bunlarla iliskili durumlar olmak üzere kanserlerin profilaktik ve terapötik tedavisi amaciyla tanida CASB616 polipeptitlerinin ve polinükleotidlerinin ve asilarin kullanimi.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9905124.5A GB9905124D0 (en) | 1999-03-05 | 1999-03-05 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
TR200102577T2 true TR200102577T2 (tr) | 2004-09-21 |
Family
ID=10849064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR2001/02577T TR200102577T2 (tr) | 1999-03-05 | 2000-02-28 | Kanser Tedavisi için Casb616 Polipeptid ve Polinücleotidlerin kullanımı |
Country Status (23)
Country | Link |
---|---|
US (1) | US20050129717A1 (tr) |
EP (2) | EP1466616A3 (tr) |
JP (1) | JP2002538218A (tr) |
KR (1) | KR20010102507A (tr) |
CN (1) | CN1374869A (tr) |
AT (1) | ATE292472T1 (tr) |
AU (1) | AU766789B2 (tr) |
BR (1) | BR0008784A (tr) |
CA (1) | CA2362370A1 (tr) |
CY (1) | CY1105585T1 (tr) |
CZ (1) | CZ20013189A3 (tr) |
DE (1) | DE60019273T2 (tr) |
ES (1) | ES2238026T3 (tr) |
GB (1) | GB9905124D0 (tr) |
HK (1) | HK1043729B (tr) |
HU (1) | HUP0200186A2 (tr) |
IL (1) | IL145046A0 (tr) |
NO (1) | NO20014292L (tr) |
NZ (1) | NZ513837A (tr) |
PL (1) | PL354143A1 (tr) |
PT (1) | PT1162993E (tr) |
TR (1) | TR200102577T2 (tr) |
WO (1) | WO2000053216A2 (tr) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002000939A2 (en) * | 2000-06-28 | 2002-01-03 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
ES2377077T3 (es) * | 2000-10-18 | 2012-03-22 | Glaxosmithkline Biologicals S.A. | Vacunas que comprenden al antígeno MAGE unido a un fragmento de proteína D |
CN1446583A (zh) * | 2002-11-29 | 2003-10-08 | 帕弗瑞生物技术(北京)有限公司 | 一种肿瘤免疫治疗及预防性疫苗的组成、制备、应用方案 |
DK2489364T3 (en) | 2003-11-06 | 2015-03-02 | Seattle Genetics Inc | Monomethylvaline compounds conjugated to antibodies |
AU2005249490B2 (en) | 2004-06-01 | 2010-07-29 | Genentech, Inc. | Antibody drug conjugates and methods |
AU2005286607B2 (en) | 2004-09-23 | 2011-01-27 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
CA2809819A1 (en) | 2009-09-09 | 2011-03-17 | Centrose, Llc | Extracellular targeted drug conjugates |
EP2528625B1 (en) | 2010-04-15 | 2013-07-10 | Spirogen Sàrl | Pyrrolobenzodiazepines and conjugates thereof |
CA2799540A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
CN103313990B (zh) | 2010-11-17 | 2016-07-20 | 基因泰克公司 | 丙氨酰美登醇抗体偶联物 |
WO2012155019A1 (en) | 2011-05-12 | 2012-11-15 | Genentech, Inc. | Multiple reaction monitoring lc-ms/ms method to detect therapeutic antibodies in animal samples using framework signature pepides |
BR112014009050B1 (pt) | 2011-10-14 | 2022-06-21 | Medimmune Limited | Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas |
WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
NZ707534A (en) | 2012-10-12 | 2018-08-31 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
US10695433B2 (en) | 2012-10-12 | 2020-06-30 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
KR101995620B1 (ko) | 2012-10-12 | 2019-07-03 | 에이디씨 테라퓨틱스 에스에이 | 피롤로벤조디아제핀-항체 컨주게이트 |
CA2887894C (en) | 2012-10-12 | 2019-10-29 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine - anti-psma antibody conjugates |
LT2839860T (lt) | 2012-10-12 | 2019-07-10 | Medimmune Limited | Pirolobenzodiazepinai ir jų konjugatai |
US10736903B2 (en) | 2012-10-12 | 2020-08-11 | Medimmune Limited | Pyrrolobenzodiazepine-anti-PSMA antibody conjugates |
NZ707490A (en) | 2012-10-12 | 2018-09-28 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-anti-cd22 antibody conjugates |
EA032986B1 (ru) | 2012-12-21 | 2019-08-30 | Медимьюн Лимитед | Пирролобензодиазепины |
AU2013366493B2 (en) | 2012-12-21 | 2017-08-24 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
TWI680766B (zh) | 2013-03-13 | 2020-01-01 | 英商梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
JP6340019B2 (ja) | 2013-03-13 | 2018-06-06 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
BR112015023333A8 (pt) | 2013-03-13 | 2018-04-17 | Medimmune Ltd | pirrolbenzodiazepinas e conjugados dos mesmos |
KR20160042080A (ko) | 2013-08-12 | 2016-04-18 | 제넨테크, 인크. | 1-(클로로메틸)-2,3-디히드로-1H-벤조[e]인돌 이량체 항체-약물 접합체 화합물, 및 사용 및 치료 방법 |
WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
EP3054985B1 (en) | 2013-10-11 | 2018-12-26 | Medimmune Limited | Pyrrolobenzodiazepine-antibody conjugates |
WO2015052532A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
MX2016007578A (es) | 2013-12-16 | 2016-10-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. |
MX371092B (es) | 2013-12-16 | 2020-01-16 | Genentech Inc | Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos. |
BR112016013861A2 (pt) | 2013-12-16 | 2017-10-10 | Genentech Inc | conjugados de droga e anticorpo, compostos, método de tratamento e composição farmacêutica |
JP6531166B2 (ja) | 2014-09-10 | 2019-06-12 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピン及びそのコンジュゲート |
TW201625688A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 經半胱胺酸改造之抗體及接合物 |
US10149913B2 (en) | 2014-09-12 | 2018-12-11 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
PE20170905A1 (es) | 2014-09-17 | 2017-07-12 | Genentech Inc | Pirrolobenzodiazepinas y conjugados de anticuerpo-disulfuro de las mismas |
CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
WO2016090050A1 (en) | 2014-12-03 | 2016-06-09 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN108700598A (zh) | 2016-03-25 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 多路总抗体和抗体缀合的药物量化测定法 |
GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
EP3465221B1 (en) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytical method for the characterization of site-specific antibody-drug conjugates |
US10639378B2 (en) | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
CN109689111B (zh) | 2016-08-11 | 2024-04-05 | 基因泰克公司 | 吡咯并苯并二氮杂䓬前药及其抗体缀合物 |
EP3522933B1 (en) | 2016-10-05 | 2021-12-15 | F. Hoffmann-La Roche AG | Methods for preparing antibody drug conjugates |
GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
PT3544636T (pt) | 2017-02-08 | 2021-05-04 | Medimmune Ltd | Conjugados de anticorpos-pirrolobenzodiazepinas |
GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
HUE059828T2 (hu) | 2017-04-18 | 2023-01-28 | Medimmune Ltd | Pirrolobenzodiazepin konjugátumok |
CA3057748A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
BR112019026564A2 (pt) | 2017-06-14 | 2020-06-30 | Adc Therapeutics Sa | regimes de dosagem para a administração de um adc anti-cd19 |
SI3668874T1 (sl) | 2017-08-18 | 2022-04-29 | Medimmune Limited | Pirolobenzodiazepinski konjugati |
KR20220156974A (ko) | 2017-09-20 | 2022-11-28 | 주식회사 피에이치파마 | 타일란스타틴 유사체 |
US11068545B2 (en) | 2017-11-17 | 2021-07-20 | Battelle Memorial Institute | Spatial identification of assets using n-dimensional asset identifiers |
GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
AU2019365238A1 (en) | 2018-10-24 | 2021-05-13 | F. Hoffmann-La Roche Ag | Conjugated chemical inducers of degradation and methods of use |
JP2022513198A (ja) | 2018-12-10 | 2022-02-07 | ジェネンテック, インコーポレイテッド | Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
WO2024138128A2 (en) | 2022-12-23 | 2024-06-27 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU766077C (en) * | 1998-11-20 | 2004-10-07 | Genentech Inc. | Uses for Eph receptor antagonists and agonists to treat vascular disorders |
-
1999
- 1999-03-05 GB GBGB9905124.5A patent/GB9905124D0/en not_active Ceased
-
2000
- 2000-02-28 EP EP04076929A patent/EP1466616A3/en not_active Withdrawn
- 2000-02-28 CN CN00807172A patent/CN1374869A/zh active Pending
- 2000-02-28 IL IL14504600A patent/IL145046A0/xx unknown
- 2000-02-28 WO PCT/EP2000/001587 patent/WO2000053216A2/en not_active Application Discontinuation
- 2000-02-28 JP JP2000603705A patent/JP2002538218A/ja active Pending
- 2000-02-28 PT PT00907633T patent/PT1162993E/pt unknown
- 2000-02-28 AU AU29153/00A patent/AU766789B2/en not_active Ceased
- 2000-02-28 BR BR0008784-0A patent/BR0008784A/pt not_active IP Right Cessation
- 2000-02-28 NZ NZ513837A patent/NZ513837A/xx unknown
- 2000-02-28 PL PL00354143A patent/PL354143A1/xx not_active Application Discontinuation
- 2000-02-28 HU HU0200186A patent/HUP0200186A2/hu unknown
- 2000-02-28 KR KR1020017011300A patent/KR20010102507A/ko not_active Application Discontinuation
- 2000-02-28 EP EP00907633A patent/EP1162993B1/en not_active Expired - Lifetime
- 2000-02-28 TR TR2001/02577T patent/TR200102577T2/tr unknown
- 2000-02-28 CZ CZ20013189A patent/CZ20013189A3/cs unknown
- 2000-02-28 DE DE60019273T patent/DE60019273T2/de not_active Expired - Fee Related
- 2000-02-28 AT AT00907633T patent/ATE292472T1/de not_active IP Right Cessation
- 2000-02-28 ES ES00907633T patent/ES2238026T3/es not_active Expired - Lifetime
- 2000-02-28 CA CA002362370A patent/CA2362370A1/en not_active Abandoned
-
2001
- 2001-09-04 NO NO20014292A patent/NO20014292L/no not_active Application Discontinuation
-
2002
- 2002-05-21 HK HK02103796.8A patent/HK1043729B/zh not_active IP Right Cessation
-
2004
- 2004-11-09 US US10/984,521 patent/US20050129717A1/en not_active Abandoned
-
2005
- 2005-05-18 CY CY20051100614T patent/CY1105585T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2000053216A2 (en) | 2000-09-14 |
DE60019273D1 (de) | 2005-05-12 |
NO20014292D0 (no) | 2001-09-04 |
EP1162993A2 (en) | 2001-12-19 |
WO2000053216A3 (en) | 2001-01-11 |
DE60019273T2 (de) | 2006-01-19 |
PT1162993E (pt) | 2005-06-30 |
KR20010102507A (ko) | 2001-11-15 |
NO20014292L (no) | 2001-10-29 |
ES2238026T3 (es) | 2005-08-16 |
BR0008784A (pt) | 2001-12-26 |
CN1374869A (zh) | 2002-10-16 |
GB9905124D0 (en) | 1999-04-28 |
EP1466616A3 (en) | 2004-12-01 |
EP1466616A2 (en) | 2004-10-13 |
CY1105585T1 (el) | 2010-07-28 |
HK1043729A1 (en) | 2002-09-27 |
AU2915300A (en) | 2000-09-28 |
NZ513837A (en) | 2003-02-28 |
ATE292472T1 (de) | 2005-04-15 |
IL145046A0 (en) | 2002-06-30 |
CZ20013189A3 (cs) | 2002-02-13 |
EP1162993B1 (en) | 2005-04-06 |
PL354143A1 (en) | 2003-12-29 |
CA2362370A1 (en) | 2000-09-14 |
US20050129717A1 (en) | 2005-06-16 |
HUP0200186A2 (en) | 2002-05-29 |
AU766789B2 (en) | 2003-10-23 |
HK1043729B (zh) | 2005-11-04 |
JP2002538218A (ja) | 2002-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR200102577T2 (tr) | Kanser Tedavisi için Casb616 Polipeptid ve Polinücleotidlerin kullanımı | |
CY1111147T1 (el) | Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου | |
MY136095A (en) | Use of human anti-ctla-4 antibodies for treatment of cancer | |
HUP0203968A2 (hu) | Készítmények és eljárások prosztatarák terápiájára és diagnózisára | |
TNSN05300A1 (en) | Treatment with anti-vegf antibodies | |
IL174047A0 (en) | Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer | |
CY2008007I1 (el) | Χρηση του et743 στην συνδυαστικη θεραπεια με δεξαμεθαζονη για την θεραπευτικη αγωγη του καρκινου | |
IS6965A (is) | Ganglíósíð-tengd raðbrigða mótefni og notkun þeirra í sjúkdómsgreiningu og meðferð á æxlum | |
AP2006003537A0 (en) | Use of polypeptides of the cupredoxin family in cancer therapy. | |
HUP0300054A1 (hu) | Daganatspecifikus állati fehérjék | |
ATE426617T1 (de) | Therapeutische und diagnostische anti-hsp 70- antikírper | |
IS7320A (is) | Peptíð ætluð til meðhöndlunar á krabbameini tengdu þekjuæxlisveiru (HPV) í manni og öðrum þekjuvefsæxlum | |
WO2003026494A3 (en) | Galectins-1-and-4 in tumor development | |
NZ500216A (en) | Beta-amyloid peptide-binding proteins and pharmaceutical use | |
IL145047A0 (en) | Casb618 polynucleotides and polypeptides and their use | |
TR200102745T2 (tr) | Yeni bileşikler | |
WO2003042700A3 (en) | Breast cancer associated polypeptide | |
WO2001023417A3 (en) | Human tumor-associated lak-4p related polynucleotides and polypeptides and their uses | |
DE60019614D1 (de) | Moraxella catarrhalis antigen basb117 | |
ZA200107282B (en) | Use of CASB616 polypeptides and polynucleotides for cancer treatment. | |
DE60019613D1 (de) | Moraxella catarrhalis antigen basb120 |